Search PubMedSearch

Biomedical subjects

Haotian Zhang

Publications and source records attributed to Haotian Zhang.

2 recordsLinked to original sources

SpliceHarmonization: an integrated method for identifying RNA splicing events in therapeutics for splicing modulation.

MOTIVATION: Splicing, a critical co-transcriptional process in eukaryotes, enhances transcriptome diversity by generating isoforms specific to cell types, tissues, or developmental stages. Recent advancements in splicing modulators have opened new avenues for targeting previously undruggable genes by inducing significant perturbations in splicing events. These developments underscore the need for comprehensive methods to accurately identify and compare splicing events. While several tools have been developed to detect local splice variants, inconsistencies across methods remain a significant challenge. To address this, we present SpliceHarmonization, an integrated approach that combines the strengths of rMATS, LeafCutter, and MAJIQ, enabling robust and reliable splicing analysis with event type annotations. RESULTS: In a comprehensive evaluation using diverse simulated datasets, SpliceHarmonization streamlined and standardized the outputs from three detection methods into a unified format, thereby improving splicing detection with event type annotation and outperforming individual methods. By integrating the outputs from rMATS, LeafCutter, and MAJIQ, our approach not only enhanced identification of a wide range of splicing events but also effectively mitigated method-specific discrepancies. This integration led to an accuracy exceeding 0.8 and a recall of up to 0.5, with an observed increase in AUC of up to 10%. Furthermore, SpliceHarmonization demonstrated high sensitivity in detecting low-abundance and complex splicing events, providing annotations including genomic coordinates and event type. AVAILABILITY AND IMPLEMENTATION: SpliceHarmonization is available at https://github.com/interactivereport/SpliceHarmonization.

RNA Splicing

Engineering TME-activated CD47-specific CAR macrophage via Arg1 promoter for safe and effective solid tumor immunotherapy.

BACKGROUND: Chimeric antigen receptor macrophage (CAR-Mφ) therapy has promising therapeutic potential in solid tumors, yet challenges remain in target compatibility and systemic toxicity. METHODS: In this study, we screened the CD47-scFv sequence of CAR-Mφ as the extracellular structure. We then constructed a classical CD47 CAR-Mφ incorporated the costimulatory domain of the α1β1 integrin-mediated Fc-gamma receptor I (FcγRI) signaling component. Subsequently, we developed a tumor microenvironment (TME)-responsive CAR macrophage platform by the arginase 1 (Arg1) promoter to target CD47, a highly expressed but clinically challenging immune checkpoint in solid tumors. RESULTS: We found that anti-CD47-scFv-mediated macrophages can effectively kill tumor cells both in vivo and in vitro. Furthermore, by integrating an α1β1 integrin-mediated FcγRI signaling domain, CD47 CAR-Mφ exhibited superior antitumor activity in hCD47+4T1 and SGC-7901 cells in vitro, which demonstrated that the CD47 CAR-Mφ was effective against solid tumors. Subsequently, Arg1-mediated activated pArg1 CD47 CAR-Mφ exhibited strong cytotoxicity against target cancer cells. We further demonstrated TME-controllable CAR gene expression in situ and induced a significant regression of established tumors in vivo. Besides, TME-dependent activation of CD47 CAR Mφ reduced the cytotoxic killing effect on erythrocytes. CONCLUSIONS: Our findings confirmed that the TME-specific activation mechanism of pArg1 CD47 CAR-Mφ based on intrinsic Arg1 promoter reprogramming endowed CAR-Mφ to effectively mitigate erythrocyte toxicity while enabling safe multidose administration regimens. This Trojan horse-like CAR-Mφ system achieves tumor-specific activation while minimizing systemic toxicity, offering a novel strategy to expand CAR-Mφ applications for solid tumors.

Animals